Capricor Therapeutics And Parent Project Muscular Dystrophy To Host Webinar To Review Latest Developments Of CAP-1002 Program
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics (NASDAQ:CAPR) will host a webinar with Parent Project Muscular Dystrophy (PPMD) to review regulatory details and provide clinical updates on its ongoing HOPE-3, Phase 3 clinical trial of CAP-1002 for treating Duchenne muscular dystrophy. The webinar will be held on October 25, 2023.
October 19, 2023 | 8:03 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Capricor's webinar to discuss updates on its CAP-1002 program could potentially influence investor sentiment and stock performance.
The webinar will provide updates on Capricor's ongoing clinical trial, which could potentially influence investor sentiment and stock performance. However, the exact impact will depend on the details shared during the webinar.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100